Bearish
$MRTX Nivolumab, marketed as Opdivo, is already on market, I don’t understand what is the value of mrtx doing this trial. If the combo not better than Nivolumab alone, then it’s pointless. Nivolumab is used as a first line treatment for inoperable or metastatic melanoma in combination with ipilimumab if the cancer does not have a mutation in BRAF,as a second-line treatment following treatment with ipilimumab and if the cancer has a mutation in BRAF, with a BRAF inhibitor,as a second-line treatment for squamous non-small cell lung cancer, and as a second-line treatment for renal cell carcinoma. Nivolumab has recently been approved for small cell lung cancer.
  • 1
  • 4